EyePoint, Inc. EYPT
Set alert
At close
Pre-market · Nov 2, 8:46 AM ET
- YTD
- -98.09%
- 1 year
- -97.34%
- Open
- 0.37
- Prev close
- 0.38
- Mkt cap
- 29.21M
- Vol
- 6.12M
- Avg vol
- 9.04M
- EPS
- -3.75
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.3446
- High
- 0.3762
- Forward P/E
- -4.89
- Beta
- 1.74
- Short ratio
- 11.44
- Inst. own
- 111.47%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 13.11
- 200-d avg
- 14.14
- 1y target
- 40.93
5D chart
Signals (141)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 3:55 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:50 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:40 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:35 PM | 2 days ago |
| RSI: Oversold | Oct 30, 3:30 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:15 PM | 2 days ago |
| RSI: Oversold | Oct 30, 3:15 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:10 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 3:10 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:00 PM | 2 days ago |
| RSI: Oversold | Oct 30, 2:00 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:35 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:00 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:25 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 11:40 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:10 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:55 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 10:35 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:30 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 9:30 AM | 3 days ago |
| RSI: Oversold | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 29, 3:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:05 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:50 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:25 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 11:55 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:55 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:10 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 11:10 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:50 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:45 AM | 3 days ago |
| RSI: Overbought | Oct 29, 10:00 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 29, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 3:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:50 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:35 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:25 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:25 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:00 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:00 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:00 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:35 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:50 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:45 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:40 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:35 AM | 4 days ago |
| RSI: Overbought | Oct 28, 10:45 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:50 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:50 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 9:50 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:45 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:35 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:35 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 9:35 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:30 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 3:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:55 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:45 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:45 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:45 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:10 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:25 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:20 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 11:30 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:25 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:20 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:15 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:05 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:25 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:20 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:15 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:15 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:10 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:10 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:00 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:00 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 6 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 6 days ago |
| SMA: Bearish | Oct 26, 3:45 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:30 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:05 PM | 6 days ago |
| RSI: Oversold | Oct 26, 3:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:45 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 2:45 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:40 PM | 6 days ago |
| RSI: Oversold | Oct 26, 1:20 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:25 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:20 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:15 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:15 PM | 6 days ago |
| SMA: Bearish | Oct 26, 11:50 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:35 AM | 6 days ago |
| SMA: Bearish | Oct 26, 11:30 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:10 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:55 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:35 AM | 6 days ago |
News
3 days ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ: EYPT). Such investors are advised to…
4 days ago zacks.com
EyePoint (EYPT) Expected to Beat Earnings Estimates: Should You Buy?
EyePoint (EYPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 days ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT). Such investors are advised to…
6 days ago globenewswire.com
EyePoint Pharmaceuticals (EYPT) Securities Investigation Notice - Levi & Korsinsky
EyePoint Pharmaceuticals shareholders lost nearly 67% of their share value in a single session after the Phase 3 LUCIA topline readout. Levi & Korsinsky is investigating potential securities law…
-
1 week ago benzinga.com
RBC Capital Maintains Sector Perform on EyePoint, Lowers Price Target to $1
RBC Capital analyst Lisa Walter maintains EyePoint (NASDAQ:EYPT) with a Sector Perform and lowers the price target from $5 to $1.
1 week ago benzinga.com
Amazon.com, Cleveland-Cliffs, Disc Medicine, Silence Therapeutics and EyePoint: Why These 5 Stocks Are on Investors' Radars Today
Major U.S. indices ended mixed on Monday, with the Dow Jones Industrial Average slipping 0.07% to 51,966.03.
1 week ago benzinga.com
Crude Oil Moves Higher; US Homebuilder Sentiment Falls In October
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 300 points on Monday.The Dow traded up 0.06% to 52,031.59 while the NASDAQ jumped 1.24% to 26,465.39.…
1 week ago benzinga.com
EyePoint Slashing Workforce, Halting Clinical Trials to Pivot Focus
EyePoint cuts 53% of staff and halts wet AMD trials after DURAVYU misses its Phase 3 primary endpoint, pivoting its focus entirely to DME.
1 week ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Silence Therapeutics (NASDAQ:SLN) stock increased by 125.6% to $19.59 during Monday's regular session. The market value of their outstanding shares is at $581.1 million. SCWorx (NASDAQ:WORX)…
2 weeks ago benzinga.com
Nasdaq Surges Over 1%; Fifth Third Bancorp Earnings Top Views
U.S. stocks mixed: Nasdaq +1.09%, S&P 500 +0.54%, Dow -0.12%. Tech led gains; utilities lagged. Oil fell, gold rose; Europe lower.
2 weeks ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Disc Medicine (NASDAQ:IRON) stock moved upwards by 50.4% to $85.51 during Monday's pre-market session. The company's market cap stands at $2.1 billion. DataMEDS AI (NASDAQ:MEDS) shares moved…
-
2 weeks ago benzinga.com
Eyepoint Says Topline Results From Lucia Phase 3 Trial Of Duravyu (Vorolanib Intravitreal Insert) For Wet Age-Related Macular Degeneration Did Not Achieve The Primary Endpoint
– LUCIA did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label aflibercept control, despite demonstrating visual improvement –– Key secondary…
1 month ago benzinga.com
Xenon Pharmaceuticals, Steel Dynamics, Nucor And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. futures rise, but Xenon plunges 27.6% after pausing psychiatry trial enrollment over neuropsychiatric adverse events; other stocks also fall
2 months ago benzinga.com
This Toast Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Wednesday
Wall Street analysts changed outlook on top companies. Check out complete rating changes, including upgrades/downgrades, on our page.
-
2 months ago benzinga.com
TD Cowen Downgrades EyePoint to Hold, Lowers Price Target to $4
TD Cowen analyst Tara Bancroft downgrades EyePoint (NASDAQ:EYPT) from Buy to Hold and lowers the price target from $20 to $4.
2 months ago benzinga.com
Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday
Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million. Other big gainers include CAPR, RZLV, CRML, and MAIR.
2 months ago benzinga.com
These Analysts Slash Their Forecasts On EyePoint
EYPT releases topline results from Phase 3 LUGANO trial for wet AMD treatment. While primary endpoint was not met, secondary endpoints showed progress. Analysts adjust price targets.
-
2 months ago benzinga.com
Citigroup Maintains Buy on EyePoint, Lowers Price Target to $17
Citigroup analyst Yigal Nochomovitz maintains EyePoint (NASDAQ:EYPT) with a Buy and lowers the price target from $35 to $17.
-
2 months ago benzinga.com
RBC Capital Downgrades EyePoint to Sector Perform, Lowers Price Target to $5
RBC Capital analyst Lisa Walter downgrades EyePoint (NASDAQ:EYPT) from Outperform to Sector Perform and lowers the price target from $37 to $5.
-
2 months ago benzinga.com
Chardan Capital Downgrades EyePoint to Neutral, Lowers Price Target to $5
Chardan Capital analyst Andreas Argyrides downgrades EyePoint (NASDAQ:EYPT) from Buy to Neutral and lowers the price target from $65 to $5.
2 months ago benzinga.com
Nike, Meta Platforms, INVO Fertility, EyePoint Pharmaceuticals, and Micron: Why These 5 Stocks Are on Investors' Radars Today
Major U.S. indices ended lower on Monday, with the Dow Jones Industrial Average falling 0.51% to 53,459.78
2 months ago benzinga.com
Why Is Ocular Therapeutix Stock Gaining Monday?
Ocular Therapeutix stock jumps 6% as rival EyePoint misses Phase 3 primary endpoint for wet AMD treatment Duravyu.
2 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers INVO Fertility (NASDAQ:IVF) shares moved upwards by 108.9% to $2.03 during Monday's regular session. The market value of their outstanding shares is at $1.7 million. As per the press release,…
-
2 months ago benzinga.com
Jefferies Maintains Buy on EyePoint, Lowers Price Target to $8
Jefferies analyst Kambiz Yazdi maintains EyePoint (NASDAQ:EYPT) with a Buy and lowers the price target from $30 to $8.
2 months ago benzinga.com
Gold Gains 1%; US Home-Builder Sentiment Edges Higher In August
US stocks mixed, S&P 500 drops 0.2%. Dow down 0.34%, NASDAQ up 0.04%. Industrials up 0.2%, consumer staples down 1%. NY Fed's Empire State Index at 20.6.
2 months ago benzinga.com
EyePoint Stock Plummets on Mixed Primary Data From Blindness Drug Study
EyePoint reported Phase 3 LUGANO trial results for DURAVYU, highlighting reduced treatment burden despite primary endpoint challenges.
2 months ago benzinga.com
Dow Falls 150 Points; NY Empire State Manufacturing Index Rises In August
US stocks mixed, Dow falls 150 points. Dow down 0.31%, NASDAQ up 0.03%, S&P 500 down 0.12%. Tech shares up 0.4%, consumer staples down 0.8%.
2 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers INVO Fertility (NASDAQ:IVF) shares increased by 163.4% to $2.56 during Monday's pre-market session. The company's market cap stands at $1.7 million. GlucoTrack (NASDAQ:GCTK) shares moved…
-
2 months ago benzinga.com
EyePoint Reports DURAVYU Non‑Inferior To Aflibercept In Ad Hoc Analysis; Primary BCVA Endpoint Not Met In Full Dataset
EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced topline…
-
2 months ago benzinga.com
EyePoint Announces Topline Results From LUGANO, First Pivotal Phase 3 Clinical Trial For DURAVYU For Treatment Of Wet Age-Related Macular Degeneration
– DURAVYU was non-inferior to on-label aflibercept control (nominal p-value = 0.0096) in an ad hoc analysis excluding a 4% asymmetric cohort (9 of 211 patients) who experienced vision loss (≥ 15…
2 months ago benzinga.com
Paycom Software To Rally Around 32%? Here Are 10 Top Analyst Forecasts For Thursday
Analysts changed outlook on top names: JP Morgan cut price target for Insulet, HC Wainwright slashed EyePoint's target, Goldman cut Sunrun's, B of A lowered Coupang's, BTIG cut Klaviyo's, Jefferies…
-
2 months ago benzinga.com
Cantor Fitzgerald Maintains Overweight on EyePoint, Raises Price Target to $55
Cantor Fitzgerald analyst Steve Seedhouse maintains EyePoint (NASDAQ:EYPT) with a Overweight and raises the price target from $47 to $55.
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on EyePoint, Lowers Price Target to $27
HC Wainwright & Co. analyst Yi Chen maintains EyePoint (NASDAQ:EYPT) with a Buy and lowers the price target from $30 to $27.
-
2 months ago benzinga.com
EyePoint Pharmaceuticals Q2 EPS $(1.09) Misses $(0.95) Estimate, Sales $507.000K Beat $406.857K Estimate
EyePoint Pharmaceuticals (NASDAQ:EYPT) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(0.95) by 14.74 percent. This is a 28.24 percent decrease over…
3 months ago benzinga.com
This Rambus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Wall Street analysts change outlook on top names. Check out analyst ratings page for upgrades, downgrades, and initiations. See how analysts view RMBS.
-
3 months ago benzinga.com
Stifel Initiates Coverage On EyePoint with Buy Rating, Announces Price Target of $40
Stifel analyst Annabel Samimy initiates coverage on EyePoint (NASDAQ:EYPT) with a Buy rating and announces Price Target of $40.
3 months ago benzinga.com
6 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
-
3 months ago benzinga.com
Cantor Fitzgerald Assumes EyePoint at Overweight, Announces Price Target of $47
Cantor Fitzgerald analyst Steve Seedhouse assumes EyePoint (NASDAQ:EYPT) with a Overweight rating and announces Price Target of $47.
-
4 months ago benzinga.com
Chardan Capital Maintains Buy on EyePoint, Raises Price Target to $65
Chardan Capital analyst Andreas Argyrides maintains EyePoint (NASDAQ:EYPT) with a Buy and raises the price target from $29 to $65.
-
5 months ago benzinga.com
RBC Capital Maintains Outperform on EyePoint, Lowers Price Target to $37
RBC Capital analyst Lisa Walter maintains EyePoint (NASDAQ:EYPT) with a Outperform and lowers the price target from $39 to $37.
-
7 months ago benzinga.com
EyePoint Files Lawsuit Against Ocular Therapeutix Alleging Defamation And Misleading Claims Over DURAVYU Clinical Results
On March 20, 2026, EyePoint, Inc. (the "Company") filed a complaint against Ocular Therapeutix, Inc. (the "Defendant") in the Middlesex County Superior Court for the Commonwealth of Massachusetts…
-
-
10 months ago benzinga.com
The Year-End 2025 Biotech Rally And What It Means For 2026
The Year-End 2025 Biotech Rally And What It Means For 2026
12 months ago benzinga.com
Earnings Scheduled For November 5, 2025
Earnings Scheduled For November 5, 2025
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
1 year ago benzinga.com
Li Auto, Xponential Fitness And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Li Auto, Xponential Fitness And Other Big Stocks Moving Lower In Friday's Pre-Market Session